Tamsulosin - Hanmi Pharmaceutical

Drug Profile

Tamsulosin - Hanmi Pharmaceutical

Alternative Names: HGP-0412; HIP-1402

Latest Information Update: 28 Oct 2016

Price : $50

At a glance

  • Originator Hanmi Pharmaceutical
  • Class Small molecules; Sulfonamides
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Benign prostatic hyperplasia

Most Recent Events

  • 16 Mar 2016 Launched for Benign prostatic hyperplasia in South Korea (PO)
  • 31 Dec 2015 Registered for Benign prostatic hyperplasia in South Korea (PO, low dose)
  • 25 Aug 2015 Hanmi Phamaceutical plans a phase I trial for Benign prostatic hyperplasia (In volunteers) in South Korea (Capsule) (NCT02529800)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top